Hospitalizationa | ||
---|---|---|
Hazard Ratio (95 % CI) | P-value* | |
Race | ||
White vs. non-white | 0.50 (0.32–0.79) | 0.003* |
Lung-function decline group | ||
Marginal decline vs. stable | 2.50 (1.06–5.91) | 0.033* |
Significant decline vs. stable | 3.37 (1.62–7.00) | <0.001* |
BMI | ||
25–30 vs. <25 | 0.59 (0.34–1.03) | 0.061 |
≥30 vs. <25 | 0.95 (0.51–1.74) | 0.861 |
Comorbidities | ||
Cardiac disorder vs. no cardiac disorder | 1.87 (1.06–3.32) | 0.032* |
Pulmonary hypertension vs. no pulmonary hypertension | 2.09 (1.15–3.83) | 0.017* |
Emphysema vs. no emphysema | 1.44 (0.62–3.36) | 0.399 |
Gastroesophageal reflux disease vs. no gastroesophageal reflux disease | 1.08 (0.67–1.73) | 0.746 |
Smoking status | ||
History of smoking vs. no history of smoking | 1.02 (0.61–1.70) | 0.935 |
Suspected AEx in the concurrent period | ||
Yes vs. no | 1.86 (1.06–3.26) | 0.030* |
Use of prednisone and azathioprine in the concurrent period | ||
Both vs. neither | 1.24 (0.59–2.62) | 0.575 |
Prednisone only vs. neither | 1.25 (0.72–2.16) | 0.428 |
Azathioprine only vs. neither | 0.74 (0.09–6.38) | 0.780 |
Symptoms at initial IPF diagnosis | ||
Dyspnea vs. no dyspnea | 1.43 (0.43–4.80) | 0.562 |
Weight loss vs. no weight loss | 1.45 (0.77–2.76) | 0.250 |
Physician's main practice setting | ||
Academic vs. non-academic | 0.89 (0.51–1.55) | 0.680 |
GAP index (per unit increase)b | 1.23 (1.04–1.46) | 0.018* |